Non-Homologous Peptides Inhibit Amyloid Beta Aggregation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current Alzheimer's treatments cannot prevent or minimize the deposition and aggregation of amyloid beta in the brain, leading to progressive neurodegeneration, despite improving learning and memory functions by modifying neurotransmitters.
Innovation Solution
Development of non-homologous peptide sequences that interact with amyloid beta and its precursor protein fragments through computer modeling, forming dimer complexes to inhibit aggregation and deposition, and targeting the catalytic site of gamma secretase enzyme.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If neurotransmitter modifiers are used to improve learning and memory, then cognitive function is improved, but amyloid beta deposition and aggregation cannot be prevented
Solution Approach 1:
The invention segments the amyloid beta peptide into specific regions (e.g., residues 1-12, 10-20, 21-31, 32-42) and designs peptides to target each segment specifically. This allows selective interference with aggregation-prone regions while preserving cognitive benefits from neurotransmitter modulation.
Solution Approach 2:
The patent introduces peptide intermediaries that bind to amyloid beta peptides and prevent their aggregation and deposition. These peptide intermediaries act as mediators between the harmful amyloid beta and the brain tissue, blocking the harmful interaction without affecting neurotransmitter function.
2Reliability
If existing Alzheimer's drugs are used, then learning and memory are improved, but neurodegeneration cannot be blocked
Solution Approach 1:
The invention applies preliminary anti-action by designing peptides that prevent amyloid beta aggregation and deposition before they can cause neurodegeneration. The peptides are designed to bind to amyloid beta in its precursor form, preventing the formation of harmful aggregates that would otherwise trigger neurodegenerative processes.
Solution Approach 2:
The patent extracts the harmful amyloid beta peptide from the brain environment through peptide binding and sequesters it into inactive complexes. This removal of amyloid beta from the synaptic and extracellular spaces prevents it from causing neurodegeneration while allowing neurotransmitter function to remain intact.
3Object-generated harmful factors
If peptide sequences are designed to interact with amyloid beta, then aggregation and deposition are inhibited, but device complexity increases
Solution Approach 1:
The invention systematically varies key parameters of the peptide sequences including amino acid composition, hydrophobicity, charge distribution, and structural conformation. By optimizing these parameters, the peptides achieve high affinity binding to amyloid beta and effective aggregation inhibition while maintaining reasonable design complexity through structured parameter variation.
Data Source
AI summary
The invented non-homologous peptide sequences are able to form dimers with corresponding amyloid beta (Aβ), its precursor protein (APP) and enzyme gamma secretase (GSA) as observed by using fixed z-axis overlay computer modeling. [The dipole moment values of these dimeric peptide structures are increased with respect to individual Aβ peptide (1-42) and APP fragments].